Staging and management of cutaneous T-cell lymphoma (Q36399825)

14 August 2017

1 reference

title

Staging and management of cutaneous T-cell lymphoma (English)

1 reference

14 August 2017

Scarisbrick JJ

1

1 reference

14 August 2017

publication date

1 March 2006

1 reference

Clinical and Experimental Dermatology

14 August 2017

published in

1 reference

14 August 2017

volume

31

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

181-186

1 reference

WHO-EORTC classification for cutaneous lymphomas

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2005.02019.X

Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2005.02019.X

Topical carmustine (BCNU) in the treatment of mycosis fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2005.02019.X

Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2005.02019.X

Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2005.02019.X

Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2005.02019.X

A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2005.02019.X

Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2005.02019.X

Optimizing bexarotene therapy for cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2005.02019.X

Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2005.02019.X

High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2005.02019.X

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2005.02019.X

Detection of a Peripheral Blood T Cell Clone is an Independent Prognostic Marker in Mycosis Fungoides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2005.02019.X

10.1111/J.1365-2230.2005.02019.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference